Bottom Line:
Author: Kathryn C. Fitzgerald, M.Sc., of the Harvard School of Public Health, Boston, and colleagues.
Background: PUFAs can help modulate inflammation and oxidative stress, mechanisms that have been implicated in the cause of ALS and other neurodegenerative diseases. But data regarding PUFA intake and ALS risk are sparse.
How the Study Was Conducted:
Results: Researchers documented 995 ALS cases during follow-up, which ranged from nine to 24 years. A greater ω-3 PUFA intake was associated with a reduced risk for ALS. Consuming both α-linolenic acid (ALA, which can be found in plant sources and nuts) and marine ω-3 PUFAs contributed to this association. Intake of ω-6 PUFAs was not associated with ALS risk.
Discussion: "Overall, the results of our large prospective cohort study suggest that individuals with higher dietary intakes of total ω-3 PUFA and ALA have a reduced risk for ALS. Further research, possibly including biomarkers of PUFA intake, should be pursued to confirm these findings and to determine whether high ω-3 PUFA intake could be beneficial in individuals with ALS."
( JAMA Neurol . Published online July 14, 2014. doi:10.1001/.jamaneurol.2014.1214. Available pre-embargo to the media at http://media.jamanetwork.com .)
Editor's Note:
Editorial: Diet and Risk of Amyotrophic Lateral Sclerosis
In a related editorial, Michael Swash, M.D., of the Royal London Hospital, England, writes: "How should this study direct our attention?"
"Fitzgerald and colleagues suggest that the fatty acid composition of cell plasma membranes, which could be measured in red cell membranes, might be important in modulating oxidative stress responses, excitotoxicity and inflammation, all factors that have been implicated in ALS and other neurodegenerative conditions," the author continues.
"As a note of caution and in contrast to their results, the authors note that in a mouse model of ALS pretreatment with high doses of eicosapentanoic acid, a long-chain ω-3 PUFA, accelerated disease progression," Swash notes.
( JAMA Neurol . Published online July 14, 2014. doi:10.1001/.jamaneurol.2014.1894. Available pre-embargo to the media at http://media.jamanetwork.com .)
Media Advisory:
To contact author Kathryn C. Fitzgerald, M.Sc., call Todd Datz at 617-432-8413 or email tdatz@hsph.harvard.edu . To contact editorial author Michael Swash, M.D., email mswash@btinternet.com .
To place an electronic embedded link to this study in your story Links for this study and editorial will be live at the embargo time: http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jamaneurol.2014.1214 and http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2014.1107 .
JAMA Neurology